|
Pronunciation |
|
(MOR
yoo ate SOW dee
um) |
|
|
U.S. Brand
Names |
|
Scleromate™ |
|
|
Generic
Available |
|
No |
|
|
Pharmacological Index |
|
Sclerosing Agent |
|
|
Use |
|
Treatment of small, uncomplicated varicose veins of the lower
extremities |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Arterial disease, thrombophlebitis, hypersensitivity to morrhuate sodium or
any component |
|
|
Warnings/Precautions |
|
Sloughing and necrosis of tissue may occur following extravasation;
anaphylactoid and allergic reactions have occurred; this drug should only be
administered by a physician familiar with proper injection techniques; a test
dose of 0.25-5 mL of a 5% injection should be given 24 hours before full-dose
treatment |
|
|
Adverse
Reactions |
|
>10%:
Cardiovascular: Thrombosis, valvular incompetency
Dermatologic: Urticaria
Local: Burning at the site of injection, severe extravasation effects
<1%: Vascular collapse, drowsiness, headache, dizziness, nausea, vomiting,
weakness, asthma, anaphylaxis |
|
|
Drug
Interactions |
|
No data reported |
|
|
Stability |
|
Refrigerate |
|
|
Mechanism of
Action |
|
Both varicose veins and esophageal varices are treated by the thrombotic
action of morrhuate sodium. By causing inflammation of the vein's intima, a
thrombus is formed. Occlusion secondary to the fibrous tissue and the thrombus
results in the obliteration of the vein. |
|
|
Pharmacodynamics/Kinetics |
|
Onset of action: ~5 minutes
Absorption: Most of the dose stays at the site of injection
Distribution: After treatment of esophageal varices, ~20% of dose distributes
to the lungs |
|
|
Usual Dosage |
|
Adults: I.V.: 50-250 mg, repeated at 5- to 7-day intervals (50-100 mg for
small veins, 150-250 mg for large veins) |
|
|
Administration |
|
For I.V. use only |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Nursing
Implications |
|
Avoid extravasation; use only clear solutions, solution should become clear
when warmed |
|
|
Dosage Forms |
|
Injection: 50 mg/mL (30 mL) |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|